Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Zhao, Qun ^a   Zhang, Hui ^a   Li, Yong ^a   Liu, Jun ^a   Hu, Xiaojie ^a   Fan, Liqiao ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; GLYCOPROTEIN P; IRINOTECAN; LIVIN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; VINCRISTINE; ANTINEOPLASTIC AGENT; BIRC7 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PLATINUM COMPLEX; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE S PHASE; CELL GROWTH; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TRANSMISSION ELECTRON MICROSCOPY; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL CYCLE; CELL PROLIFERATION; CELL SHAPE; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; IMMUNOLOGY; METABOLISM; METHODOLOGY; NUDE MOUSE; PATHOLOGY; STOMACH TUMOR; TIME; TRANSPLANTATION; TUMOR CELL LINE; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CYTOKINE-INDUCED KILLER CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, NUDE; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; P-GLYCOPROTEIN; STOMACH NEOPLASMS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956469373     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-118     Document Type: Article

References (35)

1. Testicular cancer: an oncological success story. EH Einhorn, Clin Cancer Res 1997 3 2630 2632 10068265
2. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. O Rixe W Ortuzar M Alvarez R Parker E Reed K Paull T Fojo, Biochem Pharmacol 1996 52 1855 1865 10.1016/S0006-2952(97)81490-6 8951344
3. Phase I study of oxaliplatin in patients with advanced cancer. JM Extra M Espie F Calvo C Ferme L Mignot M Marty, Cancer Chemother Pharmacol 1990 25 299 303 10.1007/BF00684890 2295116
4. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. BJ Sanderson LR Ferguson WA Denny, Mutat Res 1996 355 59 70 8781577
5. Oxaliplatin clinical activity: a review. JL Misset H Bleiberg W Sutherland M Bekradda E Cvitkovic, Crit Rev Oncol Hematol 2000 35 75 93 10.1016/S1040-8428(00)00070-6 10936465
6. Ongoing and unsaid on oxaliplatin: the hope. E Cvitkovic, Br J Cancer 1998 77 Suppl 4 8 11 9647613
7. Oxaliplatin: mechanism of action and antineoplastic activity. E Raymond S Faivre JM Woynarowski SG Chaney, Semin Oncol 1998 25 4 12 9609103
8. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. CC Chen LT Chen TC Tsou WY Pan CC Kuo JF Liu SC Yeh FY Tsai HP Hsieh JY Chang, Br J Cancer 2007 97 334 344 10.1038/sj.bjc.6603866 17609664
9. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. T Leemhuis S Wells C Scheffold M Edinger RS Negrin, Biol Blood Marrow Transplant 2005 11 181 187 10.1016/j.bbmt.2004.11.019 15744236
10. Cytokine-induced killer cells showing multidrug resistance and remaining cytotoxic activity to tumor cells after transfected with mdr1 cDNA. HF Li YH Yang YJ Shi YQ Wang P Zhu, Chin Med J (Engl) 2004 117 1348 1352 15377427
11. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. IG Schmidt-Wolf RS Negrin HP Kiem KG Blume IL Weissman, J Exp Med 1991 174 139 149 10.1084/jem.174.1.139 1711560
12. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. PH Lu RS Negrin, J Immunol 1994 153 1687 1696 7519209
13. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. C Scheffold K Brandt V Johnston P Lefterova B Degen M Schontube D Huhn A Neubauer IG Schmidt-Wolf, Bone Marrow Transplant 1995 15 33 39 7538001
14. Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. MR Verneris M Kornacker V Mailander RS Negrin, Cancer Immunol Immunother 2000 49 335 345 10.1007/s002620000111 10946816
15. Inhibition of human ovarian tumor growth by cytokine-induced killer cells. HM Kim JS Kang J Lim SK Park K Lee YD Yoon CW Lee KH Lee G Han KH Yang YJ Kim Y Kim SB Han, Arch Pharm Res 2007 30 1464 1470 10.1007/BF02977372 18087816
16. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. IG Schmidt-Wolf P Lefterova V Johnston C Scheffold M Csipai BA Mehta T Tsuruo D Huhn RS Negrin, Cell Immunol 1996 169 85 90 10.1006/cimm.1996.0094 8612299
17. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. IG Schmidt-Wolf P Lefterova BA Mehta LP Fernandez D Huhn KG Blume IL Weissman RS Negrin, Exp Hematol 1993 21 1673 1679 7694868
18. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. C Wu J Jiang L Shi N Xu, Anticancer Res 2008 28 3997 4002 19192663
19. [Growth inhibition of human hepatocellular carcinoma xenograft in nude mice by combined treatment with human cytokine-induced killer cells and chemotherapy]. M Shi L Yao FS Wang ZY Lei B Zhang WL Li JC Liu ZR Tang GD Zhou, Zhonghua Zhong Liu Za Zhi 2004 26 465 468 15555334
20. Effectiveness of immunochemotherapy for gastric cancer: a review of the current status. T Toge, Semin Surg Oncol 1999 17 139 143 10.1002/(SICI)1098- 2388(199909)17:2<139::AID-SSU9>3.0.CO;2-R 10449686
21. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. J Jiang N Xu C Wu H Deng M Lu M Li B Xu J Wu R Wang J Xu P Nilsson-Ehle, Anticancer Res 2006 26 2237 2242 16821594
22. Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer. Z Liang D Bian, Chin Med J (Engl) 1996 109 353 355 9208490
23. Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods. LY Yang JM Trujillo, Cancer Res 1990 50 3218 3225 2334917
24. Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines. K Snow W Judd, Br J Cancer 1991 63 17 28 1989661
25. Biochemistry of multidrug resistance mediated by the multidrug transporter. MM Gottesman I Pastan, Annu Rev Biochem 1993 62 385 427 10.1146/annurev.bi.62.070193.002125 8102521
26. [Drug resistance mechanism of doxorubicin-resistant human gastric cancer cells BGC-823/DOX]. G Zheng F Han X Liu, Zhonghua Wai Ke Za Zhi 1997 35 325 328 10374463
27. XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. FL Scott JB Denault SJ Riedl H Shin M Renatus GS Salvesen, EMBO J 2005 24 645 655 10.1038/sj.emboj.7600544 15650747
28. Selectively frequent expression of CXCR5 enhances resistance to apoptosis in CD8(+)CD34(+) T cells from patients with T-cell-lineage acute lymphocytic leukemia. Z Qiuping X Jie J Youxin W Qun J Wei L Chun W Jin L Yan H Chunsong Y Mingzhen G Qingping L Qun Z Kejian S Zhimin L Junyan T Jinquan, Oncogene 2005 24 573 584 10.1038/sj.onc.1208184 15580304
29. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. TM Ganten R Koschny TL Haas J Sykora M Li-Weber K Herzer H Walczak, Hepatology 2005 42 588 597 10.1002/hep.20807 16037944
30. Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. R Moriai K Asanuma D Kobayashi T Yajima A Yagihashi M Yamada N Watanabe, Anticancer Res 2001 21 595 600 11299811
31. [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel]. XJ Yan LZ Liang ZY Zeng Z Shi LW Fu, Ai Zheng 2006 25 398 403 16613669
32. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. N Zaffaroni M Pennati G Colella P Perego R Supino L Gatti S Pilotti F Zunino MG Daidone, Cell Mol Life Sci 2002 59 1406 1412 10.1007/s00018-002-8518-3 12363043
33. Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias. E Azuma S Masuda J Qi T Kumamoto M Hirayama M Nagai S Hiratake M Umemoto Y Komada M Sakurai, Eur J Haematol 1997 59 14 19 10.1111/j.1600-0609.1997.tb00954.x 9260576
34. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules. F Arienti C Gambacorti-Passerini L Borin L Rivoltini A Orazi EM Pogliani G Corneo G Parmiani, Ann Oncol 1992 3 155 162 1606087
35. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells. KA Margolin C Wright SJ Forman, Leukemia 1997 11 723 728 10.1038/sj.leu.2400646 9180298